(a) Changes in the scope of control of substances Chair: First, Commission will consider recommendations of WHO on 4 substances, namely: (a) Whether or not it wishes to include N-pyrrolidino protonitazene in Schedule I of the 1961 Convention as amended; (b) Whether or not it wishes to include N-pyrrolidino metonitazene in Schedule I of the …
WHO
CND Intersessional – Session 6 – Other Substantial Matters
2024 Thematic Discussions on the Implementation of All International Drug Policy Commitments, Following-up to the 2019 Ministerial Declaration Other Substantial Matters proposed by Member States • Challenges to the identification of new illicit drugs: Discussion on strategies and approaches by laboratories to enhance the capacity of forensic personnel and harnessing technology to improve identification methods …
CND Intersessional – Session 5 – Legal, Scientific, and Regulatory Challenges in Scheduling Substances
2024 Thematic Discussions on the Implementation of All International Drug Policy Commitments, Following-up to the 2019 Ministerial Declaration Chair: Good Morning. Secretariat: (organizational matters + scheduling 101) Moderator/intro: Mr. Justice Tettey, Chief, Drugs, Laboratory and Scientific Services Branch, UNODC: Good morning, dear colleagues. Thank you for this opportunity to address the question you posed about …
CND Intersessional – Session 2 – Synthetic Opioids and Non-medical Use of Prescription Drugs
2024 Thematic Discussions on the Implementation of All International Drug Policy Commitments, Following-up to the 2019 Ministerial Declaration Chair: Welcome back. Ms. Asma Fakhri, UNODC, on behalf of Mr. Justice TETTEY, Chief, Drugs, Laboratory and Scientific Services Branch, UNODC (Moderator): Thank you all for gathering to address the growing challenges posed by synthetic opioids and the non-medical …
CND Intersessional – Session 1 – Expanding range of drugs and synthetic opioids and nonmedical use of prescription drugs
CND Intersessional meeting – Thematic discussions on the implementation of all international drug policy commitments following up to the 2019 Ministerial Declaration Secretariat: (administrative and organizational issues) Chair: Welcome. The topics of the three days of this meeting are identified in the 2019 declaration. One of the challenges is the funding and diversification of drug …
Item 5. Implementation of the international drug control treaties (Tuesday morning)
Chair: We will consider scheduling recommendations by WHO and INCB. CND Secretariat: Recalls the substances and scheduling recommendations. Chair: Explains process to schedule substances under 1961, 1971 and 1988 conventions. Butonitazene WHO: Butonitazene, or butoxynitazene, is a benzimidazole-derived synthetic opioid not currently under international control and lacking recognized therapeutic use. It appears as a crystalline …